Somewhat Favorable News Coverage Somewhat Unlikely to Impact Ionis Pharmaceuticals (IONS) Stock Price
Media coverage about Ionis Pharmaceuticals (NASDAQ:IONS) has trended somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ionis Pharmaceuticals earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.1913051501977 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the news stories that may have impacted Accern’s scoring:
- Ionis Pharmaceuticals Inc (IONS) Director Sells $146,970.00 in Stock (americanbankingnews.com)
- Biogen (BIIB) and Ionis Pharmaceuticals, Inc. (IONS) Announce Published … (streetinsider.com)
- Ionis Pharmaceuticals to Hold 2017 Financial Results Conference Call – PR Newswire (press release) (prnewswire.com)
- Biogen (BIIB) and Ionis Pharmaceuticals, Inc. (IONS) Announce Published SPINRAZA (nusinersen) Phase 3 Study … – StreetInsider.com (streetinsider.com)
- The New England Journal of Medicine Publishes SPINRAZA® (nusinersen) Phase 3 Study Results in Individuals with Later-Onset Spinal Muscular Atrophy (finance.yahoo.com)
IONS has been the topic of several research reports. BidaskClub raised Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, December 7th. Zacks Investment Research raised Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $62.00 target price on the stock in a report on Friday, October 27th. Morgan Stanley lifted their target price on Ionis Pharmaceuticals from $45.00 to $49.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 8th. Finally, BMO Capital Markets boosted their price objective on Ionis Pharmaceuticals from $64.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 8th. Four investment analysts have rated the stock with a sell rating, six have issued a hold rating and six have given a buy rating to the company. Ionis Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $50.76.
In other Ionis Pharmaceuticals news, CFO Elizabeth L. Hougen sold 2,724 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $51.76, for a total transaction of $140,994.24. Following the sale, the chief financial officer now directly owns 17,224 shares of the company’s stock, valued at $891,514.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Patrick R. O’neil sold 645 shares of the business’s stock in a transaction that occurred on Thursday, January 25th. The shares were sold at an average price of $55.00, for a total value of $35,475.00. Following the transaction, the senior vice president now owns 15,097 shares of the company’s stock, valued at approximately $830,335. The disclosure for this sale can be found here. Insiders have sold 124,635 shares of company stock worth $6,482,681 over the last three months. 2.13% of the stock is currently owned by insiders.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.